Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924042 | 1.00 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL12762641 | 1.00 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL7926461 | 0.93 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL8204196 | 0.93 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL13326450 | 0.89 | CYP3A4 (0.49) | CYP3A4 | |
| SCHEMBL13318870 | 0.89 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL13521393 | 0.89 | — | — | |
| SCHEMBL15747003 | 0.86 | HDAC1 (0.39) | CYP3A4 | |
| SCHEMBL1943013 | 0.86 | HDAC1 (0.39) | CYP3A4 | |
| SCHEMBL13783718 | 0.86 | HDAC1 (0.39) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906513-B2 | Prevent reproduction; breaking life cycle;viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008022006-A2 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | CYP3A4 24/4885 |
| US-20090041721-A1 | serine protease inhibitors; interferons | PRSS1, SERPINB1, SPINT2 | CYP3A4 69/4885 |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | HPN, SPINT2, PRSS1 | CYP3A4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.